Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Super Lawyers Names 15 Dinsmore Attorneys to 2026 West Virginia List
CINCINNATI, Ohio, April 28 -- Dinsmore and Shohl, a law firm, issued the following news release:
* * *
Super Lawyers Names 15 Dinsmore Attorneys to 2026 West Virginia List
Fifteen Dinsmore attorneys from four of the Firm's West Virginia offices were named to the 2026 Super Lawyers and Rising Stars lists.
The attorneys named are located in Charleston, Huntington, Morgantown and Wheeling. Four attorneys were named Rising Stars for the first time, while labor and employment partner Mark Carter made the Super Lawyers list for the 20th year. He was also listed as a top attorney in his field for
... Show Full Article
CINCINNATI, Ohio, April 28 -- Dinsmore and Shohl, a law firm, issued the following news release:
* * *
Super Lawyers Names 15 Dinsmore Attorneys to 2026 West Virginia List
Fifteen Dinsmore attorneys from four of the Firm's West Virginia offices were named to the 2026 Super Lawyers and Rising Stars lists.
The attorneys named are located in Charleston, Huntington, Morgantown and Wheeling. Four attorneys were named Rising Stars for the first time, while labor and employment partner Mark Carter made the Super Lawyers list for the 20th year. He was also listed as a top attorney in his field forthe 15th time since 2007.
Dinsmore attorneys on the Super Lawyers list include:
Charleston
Mark Carter, Labor and Employment
Brian Moore, Labor and Employment
Kevin Nelson, Litigation
Ashley Pack, Labor and Employment
* * *
Morgantown
Jill Cranston Rice, Litigation, Government Relations and Health Care
Joshua Rogers, Private Client and Family Wealth Planning
Wheeling
Denise Pentino, Litigation
* * *
Rising Stars:
Charleston
Alley Cook, Real Estate
Clayton Harkins, Litigation
Jordan "Jo" McMinn, Litigation
Jared Phalen, Labor and Employment, Litigation
Sean Thomas, Labor and Employment
* * *
Huntington
Julian Pecora, Litigation
* * *
Morgantown
Chandler Aragona, Labor and Employment
Andrew Cranston, Estate and Probate
* * *
About Super Lawyers:
Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. The selection process is multi-phased and includes independent research, peer nominations and peer evaluations. Each candidate is evaluated on 12 indicators of peer recognition and professional achievement. Selections are made on an annual, state-by-state basis. The Rising Stars list recognizes attorneys who are 40 years old or younger or who have been practicing for fewer than 10 years and have gone through the Super Lawyers selection process.
* * *
Original text here: https://www.dinsmore.com/news/super-lawyers-names-15-dinsmore-attorneys-to-2026-west-virginia-list/
[Category: BizLaw/Legal]
Newmark Arranges $94 Million Financing for Repositioning of Landmark Tampa Riverwalk Hotel
NEW YORK, April 28 -- Newmark Group posted the following news release:
* * *
Newmark Arranges $94 Million Financing for Repositioning of Landmark Tampa Riverwalk Hotel
Newmark announces the Company has arranged a $94.36 million loan on behalf of Newbond Holdings and Apollo (collectively, the "Sponsor") to refinance Hotel Cala, a 281-key hospitality asset located in Downtown Tampa, Florida. The financing was provided by Bain Capital and Smith Hill Capital and was secured by Newmark Co-President, Global Debt & Structured Finance Jordan Roeschlaub, Vice Chairman Nick Scribani, Senior Managing Director
... Show Full Article
NEW YORK, April 28 -- Newmark Group posted the following news release:
* * *
Newmark Arranges $94 Million Financing for Repositioning of Landmark Tampa Riverwalk Hotel
Newmark announces the Company has arranged a $94.36 million loan on behalf of Newbond Holdings and Apollo (collectively, the "Sponsor") to refinance Hotel Cala, a 281-key hospitality asset located in Downtown Tampa, Florida. The financing was provided by Bain Capital and Smith Hill Capital and was secured by Newmark Co-President, Global Debt & Structured Finance Jordan Roeschlaub, Vice Chairman Nick Scribani, Senior Managing DirectorRicky Braha, Managing Director Tyler Dumon and Associate Tate Keir.
Hotel Cala, formerly the Hotel Tampa Riverwalk, is a seven-story property positioned in the heart of Tampa's Riverwalk District, offering direct waterfront access and proximity to the city's premier business, convention and entertainment destinations. The Sponsor is executing a comprehensive repositioning strategy, including a full renovation and rebranding of the asset into a luxury lifestyle hotel under the Curio Collection flag, with upgraded guestrooms, meeting spaces and amenity offerings, including a flagship food and beverage concept.
The Hotel is located along the 2.6-mile Tampa Riverwalk, directly overlooking the Hillsborough River. Its highly accessible position offers seamless connectivity to the Riverwalk and places it within walking distance of numerous key demand drivers, including nearly 7 million square feet of Class A office space commanding the highest rental rates in the city, the 600,000-square-foot Tampa Convention Center, Benchmark International Arena, Tampa General Hospital, the University of Tampa and Cascade Investment's $3.5 billion Water Street development, which continues to elevate Downtown Tampa and attract both group and leisure demand.
* * *
About Bain Capital
Founded in 1984, Bain Capital is one of the world's leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,900 employees, and approximately $225 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).
* * *
About Smith Hill Capital
Smith Hill Capital ("Smith Hill" or "SHC") is the fully integrated commercial real estate debt investment management business of the Procaccianti Companies (est. 1958). Smith Hill Capital was formed to invest in compelling commercial real estate debt opportunities that exist due to liquidity challenges and dislocation in commercial real estate financial markets. Smith Hill Capital is led by seasoned investment professionals who have multi-cycle investment experience and the tenured skill set to identify opportunities throughout the entire commercial real estate capital structure, spanning from securities to equity ownership. For more information, please visit www.smithhillcapital.com.
* * *
About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries ("Newmark"), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark's comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform's global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2025, Newmark generated revenues of nearly $3.3 billion. As of December 31, 2025, Newmark and its business partners together operated from approximately 175 offices with over 9,300 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.
* * *
Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
* * *
Original text here: https://www.nmrk.com/insights/press-releases/newmark-arranges-94-million-financing-for-repositioning-of-landmark-tampa-riverwalk-hotel
[Category: BizReal Estate]
FDA Approves Caplyta SNDA With Robust New Data Supporting Reduced Risk of Relapse in Schizophrenia
RARITAN, New Jersey, April 28 -- Johnson and Johnson Innovative Medicine issued the following news release on April 27, 2026:
* * *
FDA approves CAPLYTA(R) (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
CAPLYTA(R) reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months
Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA(R) studies
*
TITUSVILLE, N.J. - Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has
... Show Full Article
RARITAN, New Jersey, April 28 -- Johnson and Johnson Innovative Medicine issued the following news release on April 27, 2026:
* * *
FDA approves CAPLYTA(R) (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
CAPLYTA(R) reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months
Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA(R) studies
*
TITUSVILLE, N.J. - Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) hasapproved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of CAPLYTA(R) (lumateperone) for the prevention of relapse in schizophrenia. The data further reinforces the long-term efficacy and tolerability of CAPLYTA(R) as the latest addition to Johnson & Johnson's leading portfolio of neuropsychiatric therapies.
Relapse is one of the most consequential challenges for people living with schizophrenia--disrupting stability, undermining functioning, and often triggering episodes of psychosis, hallucinations, and other symptoms that can derail daily life for patients and their loved ones./i Schizophrenia is a complex, chronic, and progressive condition affecting approximately 2.8 million adults in the United States, yet it remains significantly undertreated, with roughly 40 percent of individuals not receiving adequate care./ii On average, adults living with schizophrenia experience nine relapse episodes within a six-year period, which is why reducing relapse risk is a critical goal in long-term management, and can help preserve functioning, reduce caregiver and societal strain, and break the cycle of repeated hospitalization./i,iii Reducing relapse also mitigates the substantial economic burden associated with the disease, as the societal cost of schizophrenia in 2024 was estimated at $366.8 billion in the U.S./iv,vi
In the Phase 3, double-blind, randomized withdrawal trial supporting this update, CAPLYTA(R) significantly extended time to relapse versus placebo during the 26-week double-blind treatment period (p=0.0002), helping support long-term stability for adults living with schizophrenia. Patients who received CAPLYTA(R) had a 63 percent lower risk of relapse compared with placebo (hazard ratio = 0.37), and 84 percent of patients were relapse-free over six months. CAPLYTA(R) also significantly delayed time to all-cause treatment discontinuation, including relapse. The safety profile remained consistent with the existing body of clinical data, and no new safety concerns were identified. The most common treatment-related adverse event was headache, which occurred in at least 5 percent of patients and at least twice the rate of placebo./v
"Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization," said Christoph U. Correll, M.D., Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York./a "These Phase 3 results--showing significantly longer time to relapse with 84% remaining relapse free over 6-months--provide clinicians with another tool that can offer long-term stability for people living with schizophrenia."
While its exact mechanism of action is unknown, CAPLYTA(R) is characterized by high serotonin 5-HT2A receptor occupancy and moderate amounts of dopamine D2 receptor occupancy at therapeutic doses. In schizophrenia short-term clinical studies, CAPLYTA(R) was similar to placebo in weight change, metabolic effects, and extrapyramidal symptoms, which are often cited as reasons for treatment discontinuation. In the Phase 3, 6-month randomized withdrawal, double-blind, placebo-controlled study, there were no clinically relevant increases in prolactin or cardiometabolic parameters at the end of the double-blind treatment period. Additionally, long-term data from a 12-month open-label extension study in schizophrenia showed that patients treated with CAPLYTA(R) experienced a mean weight change of -2.05 kg (-4.52 lbs.) over one year, with sustained improvements or stability in metabolic parameters. CAPLYTA(R) makes it easy to start and stay on treatment without the need for titration.
"People living with schizophrenia deserve treatment options that help support stability over time, not just symptom control in the short term," said Celine Goldberger, MD, PhD, Vice President Global Medical Affairs, Neuroscience, Innovative Medicine, Johnson & Johnson. "This label update--backed by long-term Phase 3 data demonstrating a significant delay in time to relapse--reinforces our commitment to advancing evidence-based therapies to support each patient's individual needs including a proven therapy that supports stability over time."
CAPLYTA(R) (lumateperone) is FDA approved in adults as an adjunctive therapy with antidepressants for major depressive disorder (MDD), schizophrenia, and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy, and as adjunctive therapy with lithium or valproate. This label update builds upon the existing clinical data and postmarketing experience across its approved uses. CAPLYTA(R) is also being evaluated in clinical studies for other neuropsychiatric and neurological conditions beyond its current FDA-approved indications.
* * *
Editor's note:
a. Christoph U. Correll, M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson. He has not been paid for any media work.
* * *
About Schizophrenia
Schizophrenia is a complex, chronic brain disorder that affects how people think, feel, speak, and act. It affects up to an estimated 2.8 million adults in the United States yet remains widely misunderstood and insufficiently treated.ii Symptoms vary by person, but confusion and distortions in perceptions, emotions, and behavior are common. Evidence shows that the first three to five years after diagnosis -- "the critical period" -- from symptom onset are key for a patient's treatment, as this is when the condition progresses most rapidly./vii,viii A comprehensive treatment plan, which may include medication, therapy, and psychosocial services, can be critical in delaying the time to relapse for adults with schizophrenia./i
* * *
About Study 304
This study was a multicenter, multi-national, double-blind, placebo-controlled, randomized withdrawal study of lumateperone for the prevention of symptomatic relapse in adult patients with schizophrenia. The study included an 18-week open-label phase where patients with schizophrenia were treated with lumateperone 42 mg per day. Patients who met the stabilization criteria during the open-label period progressed to the double-blind treatment phase. These patients were randomized to continue on lumateperone 42 mg (N=110) or switch to placebo (N=114) for up to 26 weeks or until the time to relapse occurred. The primary endpoint was time to first symptom relapse and the key secondary endpoint was time to all cause discontinuation during the double-blind phase.
* * *
About CAPLYTA(R) (lumateperone)
CAPLYTA(R) 42 mg is an oral, once daily atypical antipsychotic approved in adults as an adjunctive therapy with antidepressants for major depressive disorder (MDD), schizophrenia, and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy, and as adjunctive therapy with lithium or valproate.
While the mechanism of action of CAPLYTA(R) is unknown, the efficacy of CAPLYTA(R) could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.
* * *
INDICATIONS
CAPLYTA(R) (lumateperone) is a prescription medicine used in adults to treat: major depressive disorder (MDD) along with an antidepressant; depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) alone or with lithium or valproate; or schizophrenia.
IMPORTANT SAFETY INFORMATION
Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis.
CAPLYTA and antidepressant medicines increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any changes in these symptoms to your healthcare provider immediately.
Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).
CAPLYTA may cause serious side effects, including:
* Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.
* Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.
* Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA.
* Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels, and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity.
* Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA.
* Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position.
* Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries.
* Seizures (convulsions).
* Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities.
* Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA.
* Difficulty swallowing that can cause food or liquid to get into the lungs.
The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, dry mouth, feeling tired, and diarrhea.
These are not all the possible side effects of CAPLYTA. Tell your healthcare provider if you have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had a low white blood cell count, seizures (convulsions), or kidney or liver problems.
CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. There is a pregnancy registry for females who are exposed to CAPLYTA during pregnancy. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk.
Tell your healthcare provider about all the medicines you're taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra-Cellular Therapies, Inc. at 1-888-611-4824 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.
US-CAP-2500827
Please click here to see full Prescribing Information including Boxed Warnings (https://www.intracellulartherapies.com/docs/caplyta_pi.pdf).
* * *
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
* * *
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to product development and the potential benefits and treatment impact of CAPLYTA(R) (lumateperone). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* * *
Footnotes
i/ Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125
ii/ "Schizophrenia Fact Sheet." Treatment Advocacy Center, 10 Mar. 2025, www.tac.org/reports_publications/schizophrenia-fact-sheet/.
iii/ RWE IQVIA LAAD (Feb '18-Aug '25)
iv/ Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. Published January 2023. Accessed October 2025. Available at: https://www.psychiatrist.com/jcp/epidemiology-global-burden-schizophrenia/
v/ Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia. GlobeNewswire, 05 Nov. 2024, https://www.globenewswire.com/news-release/2024/11/05/2974784/30597/en/Intra-Cellular-Therapies-Announces-Positive-Topline-Results-in-Phase-3-Trial-Evaluating-CAPLYTA-for-the-Prevention-of-Relapse-in-Patients-with-Schizophrenia.html.
vi/ Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. 2013;16(11):1290-1299. doi: 10.3111/13696998.2013.841705
vii/ Birchwood, M. "Early intervention and sustaining the management of vulnerability." The Australian and New Zealand journal of psychiatry vol. 34 Suppl (2000): S181-4. doi:10.1080/000486700241
viii/ Tandon, Rajiv et al. "The schizophrenia syndrome, circa 2024: What we know and how that informs its nature." Schizophrenia research vol. 264 (2024): 1-28. doi:10.1016/j.schres.2023.11.015
US-CAP-2600335
* * *
Original text here: https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia
[Category: BizPharmaceuticals]
Duke Energy Commits $1 Million to Strengthen Nonprofits Helping North Carolina Customers Meet Essential Needs
CHARLOTTE, North Carolina, April 28 -- Duke Energy issued the following news release:
* * *
Duke Energy commits $1 million to strengthen nonprofits helping North Carolina customers meet essential needs
* 500,000 will be awarded to 20 nonprofits supporting seniors - applications open through May 29
* Additional $500,000 to support Share the Light Fund(R) agencies statewide
*
The Duke Energy Foundation is committing $1 million to support nonprofit organizations across North Carolina that deliver critical community services, including housing stability, food access, health care, utility assistance
... Show Full Article
CHARLOTTE, North Carolina, April 28 -- Duke Energy issued the following news release:
* * *
Duke Energy commits $1 million to strengthen nonprofits helping North Carolina customers meet essential needs
* 500,000 will be awarded to 20 nonprofits supporting seniors - applications open through May 29
* Additional $500,000 to support Share the Light Fund(R) agencies statewide
*
The Duke Energy Foundation is committing $1 million to support nonprofit organizations across North Carolina that deliver critical community services, including housing stability, food access, health care, utility assistanceand more.
Our view: "Community partners play an essential role across the state by delivering trusted, on-the-ground support and connecting neighbors to resources that help them remain safe, healthy and independent," said Kendal Bowman, Duke Energy's North Carolina president. "We're grateful for their leadership and dedication to making the communities we serve stronger."
High-impact investments
* Supporting seniors statewide: With nearly one in five North Carolinians approaching or already in retirement age, the Foundation is awarding $500,000 to support organizations that help seniors age in place and access essentials like housing assistance, food programs, transportation and benefits navigation.
- Qualifying nonprofits can apply by May 29 for $25,000 grants.
* Strengthening Share the Light Fund agencies: The Duke Energy Foundation is investing an additional $500,000 in Share the Light Fund agencies, supporting nonprofit partners that assist neighbors with utility-related needs and other essential services.
- More than $1 million has been distributed through Share the Light Fund in 2026 to date.
- Customers who would like to access funds can visit Share the Light Fund to learn more.
* * *
Duke Energy Foundation
Duke Energy Foundation provides nearly $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.
* * *
Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.7 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,700 megawatts of energy capacity. Its natural gas utilities serve 1.6 million customers in North Carolina, South Carolina, Ohio and Kentucky.
Duke Energy is executing an energy modernization strategy, keeping customer value at the forefront as it invests in electric grid upgrades and efficient generation resources to strengthen the system and serve growing energy needs.
More information is available at duke-energy.com. Follow Duke Energy on X, LinkedIn, Instagram, TikTok and Facebook for stories about the people and innovations powering its communities.
* * *
Original text here: https://news.duke-energy.com/releases/duke-energy-commits-1-million-to-strengthen-nonprofits-helping-north-carolina-customers-meet-essential-needs
[Category: BizEnergy]
Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the U.S. FDA
LONDON, England, April 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 27, 2026:
* * *
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
* Regulatory application supported by phase III B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B
* Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments
* Chronic hepatitis B is a leading
... Show Full Article
LONDON, England, April 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 27, 2026:
* * *
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
* Regulatory application supported by phase III B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B
* Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments
* Chronic hepatitis B is a leadingcause of liver cancer globally/1
* 26 October 2026 assigned by FDA as PDUFA date
*
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for priority review a New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO), for the treatment of adults with chronic hepatitis B (CHB).
Bepirovirsen has also received Breakthrough Therapy Designation (BTD), which is reserved for investigational medicines where preliminary clinical evidence indicates the potential for substantial improvement over available therapies. A BTD enables greater FDA guidance on an asset's development programme./2 The BTD for bepirovirsen builds on the Fast Track Designation also provided by the US FDA in February 2024./3 A Fast Track Designation expedites the review of drugs to treat serious conditions and fill an unmet medical need.
Chronic hepatitis B is a major public health challenge, affecting more than 250 million people worldwide/4 and an estimated 1.7 million in the United States./5 Current standard of care - typically nucleos(t)ide analogues - often requires lifelong therapy and functional cure rates remain low, typically around 1%./6 Functional cure occurs when hepatitis B virus DNA and viral protein - hepatitis B surface antigen (HBsAg) - are undetectable in the blood for at least 24 weeks after stopping all treatment, indicating that the disease is controlled by the immune system without medication. Achieving a functional cure is associated with a significant reduction in the risk of long-term complications, including liver cancer./7
The regulatory submission and BTD are supported by positive results from the Phase III B-Well 1 and B-Well 2 trials, where bepirovirsen demonstrated statistically significant and clinically meaningful functional cure rates. Functional cure rates were significantly higher with bepirovirsen plus standard of care compared to standard of care alone across all ranked endpoints, including in patients with lower baseline HBsAg levels, where an even greater effect was observed. Bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with previous studies. Data from the B-Well 1 and B-Well 2 trials will be presented at the European Association for the Study of Liver Congress (EASL) and submitted for scientific peer-reviewed publication in 2026.
The FDA has assigned 26 October 2026 as the Prescription Drug User Fee Act (PDUFA) goal date.
* * *
About chronic hepatitis B
Hepatitis B is a viral infection that can cause both acute and chronic liver disease. Chronic hepatitis B occurs when the immune system is unable to clear the virus, resulting in long-lasting infection that affects more than 250 million people worldwide. The disease causes approximately 1.1 million deaths each year globally.4 Many patients often require lifelong antiviral therapy for viral suppression; making functional cure a critical goal in disease management.
* * *
About bepirovirsen
Bepirovirsen is a triple action investigational antisense oligonucleotide designed to recognise and orchestrate the destruction of the genetic components (i.e. mRNA and pregenomic RNA) of the hepatitis B virus that can lead to chronic disease, potentially allowing a person's immune system to regain control. Bepirovirsen inhibits the replication of the viral genome in the body, suppresses the level of hepatitis B surface antigen in the blood, and stimulates the immune system to increase the chances of a durable and sustained response.
Clinical trial programme
B-Well 1 and B-Well 2 trials are global multi-centre, randomised, double-blind, placebo-controlled trials conducted in 29 countries. They assessed the efficacy, safety, pharmacokinetic profile, and the durability of functional cure in nucleos(t)ide analogue-treated participants with chronic hepatitis B and baseline surface antigen (HBsAg) 3000 IU/ml. The primary endpoint assessed the proportion of participants achieving functional cure in patients with baseline HBsAg 3000 IU/ml. A key ranked secondary endpoint evaluated functional cure in participants with baseline HBsAg 1000 IU/ml. Functional cure is defined as HBsAg being undetectable in the blood for at least 24 weeks after stopping all treatment, indicating that the disease is controlled by the immune system without medication.
Bepirovirsen is also being evaluated as a potential backbone therapy for future sequential treatment strategies aimed at expanding functional cure to broader patient populations.
GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated with them on its development. Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address significant unmet need in hepatitis B, with Fast Track Designation and Breakthrough Therapy Designation from the US FDA, Breakthrough Therapy Designation in China and SENKU Designation in Japan. Bepirovirsen is currently not approved anywhere in the world.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
* * *
References
1. Rumgay H et al . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598-1606. doi: 10.1016/j.jhep.2022.08.021
2. US Food and Drug Administration. Breakthrough Therapy. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy (last accessed March 2026)
3. GSK Press Release, available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/ (last accessed March 2026)
4. WHO. Global hepatitis report 2024. Available at: https://www.who.int/publications/i/item/9789240091672 (last accessed: March 2026)
5. Razavi-Shearer D, Gamkrelidze I, Hall S, Cohen C, Gish R, Pham T, et al. The Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling Analysis. J Viral Hepat. 2026;33(1):e70122
6. Slaets, L. et al. "Systematic review with meta-analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy" in GastroHep 2, 106-116 (2020)
7. EASL, "Clinical Practice Guidelines on the management of hepatitis B virus infection" in Journal of Hepatology Volume 83, Issue 2, August 2025, Pages 502-583. Available at: https://www.sciencedirect.com/science/article/pii/S0168827825001746 (last accessed: March 2026).
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda/
[Category: BizPharmaceuticals]
Bell Celebrates Grand Opening of the MV-75 Cheyenne Wichita Assembly Center
FORT WORTH, Texas, April 28 -- Bell Textron, a subsidiary of Textron, issued the following news release on April 27, 2026:
* * *
Bell Celebrates Grand Opening of the MV-75 Cheyenne Wichita Assembly Center
Wichita, KS - Bell Textron Inc., a Textron Inc. (NYSE:TXT) company, announced today the opening of its Wichita Assembly Center (WAC) for the MV-75 Cheyenne fuselage assembly in Wichita, KS. Bell began fuselage manufacturing operations at the facility in October of 2025, as a part of the acceleration initiative directed by the U.S. Army.
"Today's celebration marks a significant milestone for
... Show Full Article
FORT WORTH, Texas, April 28 -- Bell Textron, a subsidiary of Textron, issued the following news release on April 27, 2026:
* * *
Bell Celebrates Grand Opening of the MV-75 Cheyenne Wichita Assembly Center
Wichita, KS - Bell Textron Inc., a Textron Inc. (NYSE:TXT) company, announced today the opening of its Wichita Assembly Center (WAC) for the MV-75 Cheyenne fuselage assembly in Wichita, KS. Bell began fuselage manufacturing operations at the facility in October of 2025, as a part of the acceleration initiative directed by the U.S. Army.
"Today's celebration marks a significant milestone forthe Air Capital of the World and underscores the critical role Kansans play in supporting our national security. Wichita has deep roots in aviation and defense, and Bell Textron's presence in the community will further strengthen that legacy as Kansas workers help produce the next generation of military aircraft," said Sen. Jerry Moran. "This facility represents a new chapter of Army aviation and of Bell's investment into Kansas. I have long supported this critical program and the Army's efforts to accelerate its production. I am pleased that Bell Textron has chosen Kansas for this investment, a decision that will strengthen our national security while expanding opportunities for Wichita's highly skilled workforce."
In addition to manufacturing the MV-75 fuselage at the WAC, work is ongoing at several of Bell's other advanced manufacturing facilities in Texas, including Bell's Advanced Composite Center in Fort Worth, and final assembly in Amarillo.
"As Bell moves through the assembly of the MV-75 test aircraft and into accelerated production, we are committed to investing in advanced manufacturing to ensure we deliver exceptional performance at an affordable cost to our customer," said Danny Maldonado, President and CEO, Bell. "Textron has a rich history with the state of Kansas as well as the city of Wichita, and we are proud to deepen that relationship as we establish this new facility."
The MV-75 Cheyenne is a revolutionary capability for the U.S. Army flying twice as far and twice as fast as the current fleet and has a game-changing digital backbone and open architecture that ensures it remains on the technological forward-edge throughout its lifecycle. Bell will continue to invest in its manufacturing capability and capacity to ensure it delivers the most reliable and high-performing long-range assault aircraft to the Army, on time and at an affordable cost.
* * *
This material is based upon work supported by the Army Contracting Command - Redstone Arsenal under Contract No. W58RGZ-23-C-0001. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Army Contracting Command - Redstone Arsenal.
* * *
Original text here: https://news.bellflight.com/en-US/264901-bell-celebrates-grand-opening-of-the-mv-75-cheyenne-wichita-assembly-center/
[Category: BizNational Defense]
Ameresco Releases 2025 Impact Report, Highlighting Progress Across People, Planet, and Policy
FRAMINGHAM, Massachusetts, April 28 (TNSrpt) [Category: BizEnergy] -- Ameresco, a cleantech integrator specializing in energy efficiency and renewable energy, posted the following news release on April 27, 2026:
* * *
Ameresco Releases 2025 Impact Report, Highlighting Progress Across People, Planet, and Policy
Report reflects a quarter century of results - over $16 billion in energy solutions delivered, 140+ million cumulative metric tons of CO2e avoided, over 3,700 employee volunteer hours, and continued momentum across sustainability, workforce development, and governance
*
Ameresco, Inc.,
... Show Full Article
FRAMINGHAM, Massachusetts, April 28 (TNSrpt) [Category: BizEnergy] -- Ameresco, a cleantech integrator specializing in energy efficiency and renewable energy, posted the following news release on April 27, 2026:
* * *
Ameresco Releases 2025 Impact Report, Highlighting Progress Across People, Planet, and Policy
Report reflects a quarter century of results - over $16 billion in energy solutions delivered, 140+ million cumulative metric tons of CO2e avoided, over 3,700 employee volunteer hours, and continued momentum across sustainability, workforce development, and governance
*
Ameresco, Inc.,(NYSE: AMRC), a leading energy infrastructure solutions provider, today announced the release of its 2025 Impact Report centered on the theme of "25 Years of Impact." The report details fiscal year 2025 performance and progress across Ameresco's three impact pillars - People, Planet, and Policy - underpinned by a quarter century of delivering solutions that reduce energy costs, strengthen resilience, and create lasting value.
"Since 2000, Ameresco has operated on the belief that sustainability, resilience, and sound financial decision-making are fundamentally connected," said George Sakellaris, Chairman of the Board and Chief Executive Officer of Ameresco. "Our twenty-fifth year in business reflected that conviction, backed by a best-in-class team who deliver long-term value to our customers. I am proud of the impact we continue to make and excited by the scale of what's ahead in energizing a sustainable world."
Key highlights from the 2025 Impact Report include:
* People: People are the foundation of Ameresco's success, and central to the Company's 25 years of impact. Through our One Ameresco culture, we foster creativity and collaboration across a global team, invest in mentorship, training, safety, and employee satisfaction, and extend our C.A.R.I.N.G. values into the communities we serve.
* Planet: Ameresco's track record is defined by helping customers navigate real-world energy challenges: reducing consumption, improving resilience, and lowering emissions at scale. Approximately 18 million metric tons of carbon dioxide equivalent were avoided during 2025 from Ameresco's owned energy assets and customer projects. We continue to advance our customers' climate action journeys and measure our own carbon footprint amid an increasingly complex energy landscape.
* Policy: Good governance is essential to Ameresco's sustainable growth and 25-year track record of execution. From Board oversight and risk management to cybersecurity, compliance, and responsible public policy engagement in a dynamic regulatory environment, our practices are built on transparency, accountability, and the highest ethical standards.
"Impact is about whether what we build matters over time: helping customers lower energy use, improve reliability, and meet their goals in a way that lasts," said Mark Chiplock, Executive Vice President, Chief Financial Officer, and Executive Chair of Ameresco's Ambassadors of Impact. "This year's Impact Report reflects on our continued commitment to responsible growth, measurable progress, and strong governance as the global energy transition accelerates."
* * *
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering energy infrastructure solutions to Federal, state and local governments, utilities, data centers, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.
* * *
REPORT: http://www.ameresco.com/wp-content/uploads/2026/04/Ameresco-2025-Impact-Report-Final.pdf
* * *
Original text here: https://www.ameresco.com/ameresco-releases-2025-impact-report-highlighting-progress-across-people-planet-and-policy/
